噬菌体疗法及其在皮肤和泌尿生殖道感染中的应用与展望

doi:10.35541/cjd.20191116

摘要/Abstract

摘要： 【摘要】随着耐药菌的大量出现，给临床抗感染治疗带来严峻挑战。噬菌体疗法被认为是能够应对这种困境非常有希望的方法，已在很多学科得到探索和应用，在清除皮肤黏膜感染方面的疗效也得到证实，成为目前国际研究的热点。应用多种噬菌体混合的鸡尾酒疗法、噬菌体内溶酶以及噬菌体蛋白治疗耐药的金黄色葡萄球菌、铜绿假单胞菌、大肠杆菌、克雷伯菌、变形杆菌等获得良好的效果。本文综述噬菌体疗法的背景、特征、发展特点及其在皮肤和泌尿生殖道感染中的应用和前景。

关键词: 感染, 细菌噬菌体, 抗药性, 微生物, 皮肤, 泌尿道感染, 生殖道感染, 治疗

Abstract: 【Abstract】 The emergence of a large number of drug-resistant bacteria has brought severe challenges to clinical anti-infection treatment. Phage therapy is considered to be a very promising method to cope with this dilemma. It has been explored and applied in many disciplines, its efficacy has also been confirmed in clearing skin and mucous membrane infections, and it has become a hot spot in international research. The use of phage cocktails, phage lysozyme and phage proteins has shown good efficacy in the treatment of drug-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Klebsiella, Bacillus proteus, etc. This review summarizes the background, characteristics, development of phage therapy, and its application and prospects in skin and genitourinary tract infections.

Key words: Infection, Bacteriophages, Drug resistance, microbial, Skin, Urinary tract infections, Reproductive tract infections, Therapy

邵丽丽刘全忠. 噬菌体疗法及其在皮肤和泌尿生殖道感染中的应用与展望[J]. 中华皮肤科杂志, 2021, 54(10): 924-927.doi:10.35541/cjd.20191116

Shao Lili, Liu Quanzhong. Phage therapy and its application and prospects in skin and genitourinary tract infections[J]. Chinese Journal of Dermatology, 2021, 54(10): 924-927.doi:10.35541/cjd.20191116

参考文献 25

［1］	Lee AS, de Lencastre H, Garau J, et al. Methicillin⁃resistant Staphylococcus aureus［J］. Nat Rev Dis Primers, 2018,4:18033. doi: 10.1038/nrdp.2018.33.
［2］	Luepke KH, Suda KJ, Boucher H, et al. Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications［J］. Pharmacotherapy, 2017,37（1）:71⁃84. doi: 10.1002/phar.1868.
［3］	Jamal M, Bukhari S, Andleeb S, et al. Bacteriophages: an overview of the control strategies against multiple bacterial infections in different fields［J］. J Basic Microbiol, 2019,59（2）:123⁃133. doi: 10.1002/jobm.201800412.
［4］	Chanishvili N. Phage therapy⁃⁃history from Twort and d′Herelle through Soviet experience to current approaches［J］. Adv Virus Res, 2012,83:3⁃40. doi: 10.1016/B978⁃0⁃12⁃394438⁃2.00001⁃3.
［5］	Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy.Antimicrob Agents Chemother, 2001,45（3）:649⁃659. doi: 10. 1128/AAC.45.3.649⁃659.2001.
［6］	Almeida GM, Leppänen M, Maasilta IJ, et al. Bacteriophage imaging: past, present and future［J］. Res Microbiol, 2018,169（9）:488⁃494. doi: 10.1016/j.resmic.2018.05.006.
［7］	安瑞. 噬菌体治疗的前世、今生与未来——对话微生物学界噬菌体专家［J］. 科学通报, 2017,62（23）:2577⁃2580.
［8］	Nilsson AS. Phage therapy⁃⁃constraints and possibilities［J］. Ups J Med Sci, 2014,119（2）:192⁃198. doi: 10.3109/03009734.2014. 902878.
［9］	Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics［J］. Trends Biotechnol, 2010,28（12）:591⁃595. doi: 10.1016/j.tibtech.2010.08. 001.
［10］	Weber⁃Dabrowska B, Mulczyk M, Górski A. Bacteriophage therapy of bacterial infections: an update of our institute′s experience［J］. Arch Immunol Ther Exp （Warsz）, 2000,48（6）:547⁃551.
［11］	Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa （PhagoBurn）: a randomised, controlled, double⁃blind phase 1/2 trial. Lancet Infect Dis, 2019,19（1）:35⁃45. doi:10.1016/S1473⁃3099（18）30482⁃1.
［12］	Morozova VV, Vlassov VV, Tikunova NV. Applications of bacteriophages in the treatment of localized infections in humans［J］. Front Microbiol, 2018,9:1696. doi: 10.3389/fmicb. 2018.01696.
［13］	Markoishvili K, Tsitlanadze G, Katsarava R, et al. A novel sustained⁃release matrix based on biodegradable poly（ester amide）s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds［J］. Int J Dermatol, 2002,41（7）:453⁃458. doi:10.1046/j.1365⁃4362.2002.01451.x
［14］	Rhoads DD, Wolcott RD, Kuskowski MA, et al. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial［J］. J Wound Care, 2009,18（6）:237⁃238,240⁃243. doi: 10.12968/jowc.2009.18.6.42801.
［15］	Morozova VV, Kozlova YN, Ganichev DA, et al. Bacteriophage treatment of infected diabetic foot ulcers［J］. Methods Mol Biol, 2018,1693:151⁃158. doi: 10.1007/978⁃1⁃4939⁃7395⁃8_13.
［16］	Fish R, Kutter E, Wheat G, et al. Compassionate use of bacteriophage therapy for foot ulcer treatment as an effective step for moving toward clinical trials［J］. Methods Mol Biol, 2018,1693:159⁃170. doi: 10.1007/978⁃1⁃4939⁃7395⁃8_14.
［17］	Totté J, van Doorn MB, Pasmans S. Successful Treatment of Chronic Staphylococcus aureus⁃related dermatoses with the topical endolysin Staphefekt SA.100: a report of 3 cases［J］. Case Rep Dermatol, 2017,9（2）:19⁃25. doi: 10.1159/000473872.
［18］	van Bijnen EM, Paget WJ, den Heijer CD, et al. Primary care treatment guidelines for skin infections in Europe: congruence with antimicrobial resistance found in commensal Staphylococcus aureus in the community［J］. BMC Fam Pract, 2014,15:175. doi: 10.1186/s12875⁃014⁃0175⁃8.
［19］	首例超级细菌感染患者经噬菌体治疗痊愈［EB/OL］. ［2019⁃05⁃25］. http://www.sh.chinanews.com/yljk/2018⁃08⁃15/43418.shtml.
［20］	Kuipers S, Ruth MM, Mientjes M, et al. A Dutch case report of successful treatment of chronic relapsing urinary tract infection with bacteriophages in a renal transplant patient［J］. Antimicrob Agents Chemother, 2019,64（1）:e01281⁃19. doi: 10. 1128/AAC. 01281⁃19.
［21］	Rostkowska OM, Międzybrodzki R, Miszewska⁃Szyszkowska D, et al. Treatment of recurrent urinary tract infections in a 60⁃year⁃old kidney transplant recipient. The use of phage therapy［J］. Transpl Infect Dis, 2020:e13391. doi: 10.1111/tid.13391.
［22］	Leitner L, Sybesma W, Chanishvili N, et al. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo⁃controlled, double⁃blind clinical trial［J］. BMC Urol, 2017,17（1）:90. doi: 10.1186/s12894⁃017⁃0283⁃6.
［23］	Zalewska⁃Piątek B, Piątek R. Phage therapy as a novel strategy in the treatment of urinary tract infections caused by E. Coli［J］. Antibiotics （Basel）, 2020,9（6）:304. doi: 10.3390/antibiotics906 0304.
［24］	Bhattarai SR, Yoo SY, Lee SW, et al. Engineered phage⁃based therapeutic materials inhibit Chlamydia trachomatis intracellular infection［J］. Biomaterials, 2012,33（20）:5166⁃5174. doi: 10.1016/ j.biomaterials.2012.03.054.
［25］	练婷婷, 魏世娟, 刘原君, 等. M13⁃IN5重组噬菌体的构建与鉴定及其对沙眼衣原体的作用研究［J］. 中华皮肤科杂志,2018,51（12）:859⁃864. doi: 10.3760/cma.j.issn.0412⁃4030.2018. 12.002.

[1]	吴煜昊张国龙王秀丽. 三级淋巴结构在恶性黑素瘤中的研究进展[J]. 中华皮肤科杂志, 2021, 54(9): 827-830.
[2]	刘倩李国宏陈炳为. 非黑素瘤皮肤癌患者生活质量及影响因素调查[J]. 中华皮肤科杂志, 2021, 54(9): 819-821.
[3]	王逸飞耿怡缪秋菊宋昊徐秀莲孙建方. 黏蛋白痣10例临床病理分析[J]. 中华皮肤科杂志, 2021, 54(9): 804-807.
[4]	张莹李思琪甘璐孔英琪李颜陈浩孙建方. 外周血流式细胞仪分析在淋巴瘤性红皮病诊断中的作用研究[J]. 中华皮肤科杂志, 2021, 54(9): 808-813.
[5]	龙海蒋丽邱月棨姚南刘力聪谢昱明熊峰谭思齐匡琪琪尤睿璇柴可罗鑫龙浩君忻悦郭子瑜王佳琪谭怡忻张庆张桂英李亚萍苏玉文肖嵘陆前进, . 皮肤科病房危重症1 057例临床分析[J]. 中华皮肤科杂志, 2021, 54(9): 790-797.
[6]	邱月棨付思祺罗帅寒天李亚萍张桂英. 2020年雄激素性脱发的研究进展[J]. 中华皮肤科杂志, 2021, 54(9): 835-838.
[7]	中国医师协会皮肤科医师分会自身免疫性疾病学组. 环磷酰胺治疗自身免疫性皮肤病中国专家共识[J]. 中华皮肤科杂志, 2021, 54(9): 765-770.
[8]	中华医学会医学美学与美容学分会激光美容学组中华医学会皮肤性病学分会美容激光学组中国医师协会美容与整形医师分会激光学组. 中国痤疮瘢痕治疗专家共识（2021）[J]. 中华皮肤科杂志, 2021, 54(9): 747-756.
[9]	张晓付萌王雷刘宇高天文刘玲. 临床误诊的皮肤黑素瘤118例分析[J]. 中华皮肤科杂志, 2021, 54(9): 771-776.
[10]	中华医学会皮肤性病学分会皮肤肿瘤研究中心中国医师协会皮肤科医师分会皮肤肿瘤学组. 皮肤基底细胞癌诊疗专家共识（2021）[J]. 中华皮肤科杂志, 2021, 54(9): 757-764.
[11]	陈凤鸣亢寒梅高天文付萌王雷刘玲. 先天性色素痣伴增生性结节10例临床病理分析[J]. 中华皮肤科杂志, 2021, 54(9): 785-789.
[12]	郭伟赵涛郭伟楠马翠玲高天文赵建红李冰. 早期甲黑素瘤115例手术治疗方案和预后回顾分析[J]. 中华皮肤科杂志, 2021, 54(9): 777-784.
[13]	王大光蒋佳怡. 几种甲病诊疗的思考[J]. 中华皮肤科杂志, 2021, 54(8): 733-737.
[14]	李婷徐明圆吴飞梁豫琳刘业强. 204例皮角患者组织病理与临床分析[J]. 中华皮肤科杂志, 2021, 54(8): 677-682.
[15]	胡枫陈柳青王巍郑芳. COVID-19流行期间武汉某医院皮肤科门诊患者流行病学特点及疾病谱分析[J]. 中华皮肤科杂志, 2021, 54(8): 719-722.